KR880002037B1 - 인터페론 조성물 및 이의 제조방법 - Google Patents
인터페론 조성물 및 이의 제조방법 Download PDFInfo
- Publication number
- KR880002037B1 KR880002037B1 KR8205702A KR820005702A KR880002037B1 KR 880002037 B1 KR880002037 B1 KR 880002037B1 KR 8205702 A KR8205702 A KR 8205702A KR 820005702 A KR820005702 A KR 820005702A KR 880002037 B1 KR880002037 B1 KR 880002037B1
- Authority
- KR
- South Korea
- Prior art keywords
- interferon
- composition
- glycine
- alanine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000014150 Interferons Human genes 0.000 title claims description 64
- 108010050904 Interferons Proteins 0.000 title claims description 64
- 229940079322 interferon Drugs 0.000 title claims description 60
- 239000000203 mixture Substances 0.000 title claims description 50
- 238000002360 preparation method Methods 0.000 title claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 239000004471 Glycine Substances 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 18
- 108010047761 Interferon-alpha Proteins 0.000 claims description 14
- 102000006992 Interferon-alpha Human genes 0.000 claims description 14
- 239000007853 buffer solution Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000008223 sterile water Substances 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 150000002333 glycines Chemical class 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940047124 interferons Drugs 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108010086003 delta interferon Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- IPIGTJPBWJEROO-UHFFFAOYSA-B thorium(4+);tetraphosphate Chemical compound [Th+4].[Th+4].[Th+4].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O IPIGTJPBWJEROO-UHFFFAOYSA-B 0.000 description 1
- JUWGUJSXVOBPHP-UHFFFAOYSA-B titanium(4+);tetraphosphate Chemical compound [Ti+4].[Ti+4].[Ti+4].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JUWGUJSXVOBPHP-UHFFFAOYSA-B 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33405281A | 1981-12-23 | 1981-12-23 | |
| US334.052 | 1981-12-23 | ||
| US334,052 | 1981-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR840002657A KR840002657A (ko) | 1984-07-16 |
| KR880002037B1 true KR880002037B1 (ko) | 1988-10-13 |
Family
ID=23305374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR8205702A Expired KR880002037B1 (ko) | 1981-12-23 | 1982-12-20 | 인터페론 조성물 및 이의 제조방법 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS58146504A (enExample) |
| KR (1) | KR880002037B1 (enExample) |
| ZA (2) | ZA828580B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60228422A (ja) * | 1984-04-26 | 1985-11-13 | Suntory Ltd | 安定化された生理活性物質製剤 |
| JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
| IL80288A0 (en) * | 1985-10-15 | 1987-01-30 | Hoffmann La Roche | Stabilized interferon compositions and their manufacture |
| JP2577744B2 (ja) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
| JPS6391331A (ja) * | 1986-10-03 | 1988-04-22 | Senjiyu Seiyaku Kk | 眼科用水性組成物 |
| CA1327161C (en) * | 1987-09-01 | 1994-02-22 | Mitsugu Kobayashi | Lyophilized pharmaceutical composition of neocarzinostatin derivative |
| AU3857095A (en) * | 1994-11-29 | 1996-06-19 | Kyowa Hakko Kogyo Co. Ltd. | Indolocarbazole derivative preparation |
| DE60305438T2 (de) * | 2002-02-01 | 2006-12-21 | Shimoda Biotech (Pty.) Ltd., Mill Park | Lyophilisierte pharmazeutische zusammensetzung von propofol |
| CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55102519A (en) * | 1979-01-31 | 1980-08-05 | Green Cross Corp:The | Stabilization of interferon |
-
1982
- 1982-11-19 ZA ZA828580A patent/ZA828580B/xx unknown
- 1982-12-20 ZA ZA829344A patent/ZA829344B/xx unknown
- 1982-12-20 KR KR8205702A patent/KR880002037B1/ko not_active Expired
- 1982-12-21 JP JP57224785A patent/JPS58146504A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0543689B2 (enExample) | 1993-07-02 |
| ZA829344B (en) | 1983-10-26 |
| JPS58146504A (ja) | 1983-09-01 |
| KR840002657A (ko) | 1984-07-16 |
| ZA828580B (en) | 1983-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0082481B1 (en) | Stabilised alpha-interferon formulations and their preparation | |
| US5744132A (en) | Formulations for IL-12 | |
| CA1330301C (en) | Stabilised human protein preparations | |
| EP0762897B1 (en) | Method of preventing aggregation of proteins/peptides upon rehydration or thawing | |
| EP1308170B1 (en) | Dried blood factor composition comprising trehalose | |
| WO1996024369A9 (en) | Formulations for il-12 | |
| KR100707713B1 (ko) | Ｈｇｆ 동결 건조 제제 | |
| AU677773B2 (en) | Gonadotropin containing pharmaceutical compositions with sucrose stabilizer | |
| US4895716A (en) | Stabilized formulations of gamma interferons | |
| JPH08245418A (ja) | 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法 | |
| EP0641216B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING IL-6 stabilized with a non-reducing sugar | |
| KR880002037B1 (ko) | 인터페론 조성물 및 이의 제조방법 | |
| KR900004799B1 (ko) | 안정한 감마 인터페론 제제 및 이의 제조방법 | |
| US20030118548A1 (en) | Human interferon-beta formulations | |
| HU205555B (en) | Process for producing stabilized leukocyte interferons | |
| JPS60260523A (ja) | インタ−フエロンの凍結乾燥医薬組成物 | |
| WO2002060475A1 (en) | Methods for stabilizing lyophilized blood proteins | |
| JPS62149623A (ja) | 安定なｇｒｆ製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19821220 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19870923 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19821220 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19880601 Patent event code: PE09021S01D |
|
| G160 | Decision to publish patent application | ||
| PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19880909 |
|
| O035 | Opposition [patent]: request for opposition | ||
| PO0301 | Opposition |
Comment text: Request for Opposition Patent event code: PO03011R01D Patent event date: 19881213 |
|
| O073 | Decision to grant registration after opposition [patent]: decision to grant registration | ||
| PO0701 | Decision to grant registration after opposition |
Comment text: Decision to Grant Registration Patent event code: PO07011S01D Patent event date: 19890725 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19890809 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19890809 End annual number: 3 Start annual number: 1 |
|
| PR1001 | Payment of annual fee |
Payment date: 19911008 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 19921012 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 19931004 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 19941007 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 19950927 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 19960924 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 19970930 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 19980923 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 19991002 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20001006 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20010928 Start annual number: 14 End annual number: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20021010 Year of fee payment: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20021010 Start annual number: 15 End annual number: 15 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20030909 Termination category: Expiration of duration |